SCHEMBL4928593

SCHEMBL4928593

CCCCCc1cccc[n+]1[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 10/20 0.53
ALDH1A1 P00352 1/20 0.42
LIPG Q9Y5X9 1/20 0.38
CFTR P13569 1/20 0.37
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
HSD11B1 P28845 1/20 0.36
ABCB11 O95342 1/20 0.35
ESR1 P03372 1/20 0.35
PGR P06401 1/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD1 P21728 1/20 0.35
TBXA2R P21731 1/20 0.35
ACHE P22303 1/20 0.35
PTGS1 P23219 1/20 0.35
SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11338813 0.98 KCNH2 (0.56) KCNH2ALDH1A1LIPGHTTABCB11
SCHEMBL29192036 0.98 KCNH2 (0.56) KCNH2ALDH1A1LIPGHTTABCB11
SCHEMBL9440072 0.98 KCNH2 (0.56) KCNH2ALDH1A1LIPGHTTABCB11
SCHEMBL1462481 0.98 KCNH2 (0.56) KCNH2ALDH1A1LIPGHTTABCB11
SCHEMBL1461158 0.98 KCNH2 (0.56) KCNH2ALDH1A1LIPGHTTABCB11
SCHEMBL5234381 0.94 KCNH2 (0.46) KCNH2ALDH1A1CFTRLMNAHTT
SCHEMBL2552339 0.86 ALDH1A1 (0.46) KCNH2ALDH1A1CFTRLMNAHTT
SCHEMBL14732897 0.86 ALDH1A1 (0.48) KCNH2ALDH1A1LMNAHTT
SCHEMBL3942383 0.81 ALDH1A1 (0.42) KCNH2ALDH1A1CFTRLMNAHTT
SCHEMBL8241097 0.80 ALDH1A1 (0.42) KCNH2ALDH1A1LMNAHTTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106660967-A Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne 西纳福克斯股份有限公司 2017-05-10 CN disclosed
US-20080132698-A1 Use of N-oxide compounds in coupling reactions UNIVERSITY OF OTTAWA 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132698-A1 Use of N-oxide compounds in coupling reactions CYP4X1, CYP4F3, CYP1A2 KCNH2 490/4885ALDH1A1 1518/4885LIPG 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.